Second China Lifestyle Medicine Conference Guangzhou Forum and Greater Bay Area Health & Life Sciences Industry-Finance Summit Successfully Concluded

As part of the conference’s overall agenda, we have invited numerous distinguished guests to engage in in-depth, multidisciplinary, and high-level dialogues and exchanges.

At the outset of the summit, cancer biologist, Foreign Associate of the Chinese Academy of Sciences, and Tenured Chair Professor at Duke UniversityWang Xiaofan, Vice President of Guang'anmen Hospital, China Academy of Chinese Medical SciencesYang Rui, President of the Asian Sleep Research SocietyHan Fang, Director of the Cardiac Rehabilitation Center at Fuwai Hospital, Chinese Academy of Medical SciencesFeng XueDeliver a speech via video.

Deputy Inspector Shi Pengfei, Guangzhou Municipal Science and Technology Bureau

Subsequently, byShi Pengfei, Guangzhou Municipal Science and Technology BureauDeputy InspectorandSu Zhenbo, Founding Partner of Danlu CapitalDeliver the opening remarks.

Deputy Inspector Shi Pengfei stated that this event has brought together enterprises, investment institutions, and research institutes, and will officially establish the Guangzhou Big Health and Life Science Industry-Finance Alliance. He expressed the hope that all attendees will fully leverage Guangzhou’s advantages in the biomedical industry, engage in ideological exchange and cross-sector integration, promote the transformation of more outstanding scientific and technological achievements in Guangzhou’s biomedical sector, and contribute to building a new development paradigm.

Su Zhenbo, Founding Partner of Danlu CapitalNext, Su Zhenbo, Founding Partner of Danlu Capital, stated that over the past two decades, the growth of China’s healthcare industry has been remarkable, driven by talent development and technological advancements. Guangzhou, where we are based, serves as the core of the Greater Bay Area, gathering leading medical institutions, universities of science and technology, and research institutes across China. An increasing number of listed companies and high-quality enterprises are emerging from this region.

As a native of Guangzhou, I take great pride in my roots. In 2018, Lu Qinchao and I founded Danlu Capital in Guangzhou, marking both our homecoming and a strategic bet on the widely recognized potential of the Greater Bay Area. Danlu Capital remains deeply committed to early-stage investments in the healthcare and wellness sector. We aim to empower outstanding medical professionals, industry leaders, and medical research institutions to contribute to the advancement of the healthcare ecosystem. Our vision is to establish a strong foundation in Guangzhou, serve the Greater China region, and ultimately expand our impact globally.

Guangzhou Big Health and Life Sciences Industry-Finance Alliance。

Supported by the Guangdong Zhong Nanshan Medical Foundation, the alliance was launched at the ceremony. Representatives of the initiating organizations participated in the launch ceremony and witnessed the establishment of the Guangzhou Health and Life Science Industry-Finance Alliance. These representatives included Shi Pengfei, Deputy Inspector of the Guangzhou Municipal Science and Technology Bureau; Bai Defa, Deputy Director of the Science and Technology Department of Jinan University; Xie Zhi, Executive Vice President of the National Institute of Health and Medical Big Data at Sun Yat-sen University; Deng Wanjun from Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Gao Yi, Director of the Institute of Regenerative Medicine at Southern Medical University; Ren Li, Vice Dean of the School of Materials Science and Engineering at South China University of Technology; Liu Junzhe, Head of the Expansion Department of the Guangdong Zhong Nanshan Medical Foundation; Tan Shengchen, Senior Manager of the Investment Development Center at By-Health Co., Ltd.; Wang Jihua, Chairman of Wondfo Biotech; Lei Wen, Director of Jafron Group; Lin Yiwei, General Manager of Huangpu Investment Holdings; Mao Jie, President of Xiangrong Capital; Qiu Bingqiang, Deputy General Manager of the Government Fund Department of Guangzhou Financial Holdings Fund; Zhang Zhengxi, Founding Partner of Yuanhe Capital; Wang Ting, Vice President of the Guangdong Changjiang Health Club; Lu Qinchao, Founding and Managing Partner of Danlu Capital; and Yang Hua, CEO of Qingsong Club.

Founding Member of the Guangzhou Alliance for Industry-Finance Integration in Big Health and Life Sciences

In the future, the Guangzhou Big Health and Life Science Industry-Finance Alliance will integrate innovative research institutions in healthcare and life sciences across the Pearl River Delta region. It aims to explore viable pathways and build bridges for efficient collaboration to foster the incubation and development of innovative achievements in Guangzhou’s biopharmaceutical and medical technology sectors.

The conference is structured into two major segments—“New Medical Technologies” and “Innovative Drugs”—and features five roundtable forums. Topics cover healthy living and healthcare, high-end medical equipment and consumables, digital health, cell and gene therapy, and AI empowerment. Renowned medical experts, industry leaders, and representatives from high-growth enterprises from both China and abroad are invited to discuss the development of the healthcare industry.

Host: Lu Qinchao

Guest: 

● Vice President (Part-time) of the Chinese Preventive Medicine Association,

● Liang Xiaofeng, Dean of the Vaccine Industry Research Institute, Jinan University

● Zhang Zhengxi, President-Elect of a Specialty Branch of the Chinese Medical Association; Founding Partner of Yuanhe Capital; Vice Chairman of the China Venture Capital and Private Equity Association

● Wang Chuhuai, Chairman of the Branch of Physical Medicine and Rehabilitation, Guangdong Medical Association

● Liu Xu, Vice President of New Hope Investment Group; Xiao E, Founder & CTO of Meibai Bio

Host: Xu Qiang

Guest： 

● Former Vice Chairman of the China Board of Directors of AdvaMed, Sun Jianguo

● Zhang Mingdong, Chief Medical Officer for Boston Scientific Asia Pacific and Vice President of Medical Affairs

● Zhang Yong, Visiting Professor at the National Clinical Research Center for Respiratory Diseases

● Yang Rongqian, Vice Chairman and Secretary-General of the Guangdong Biomedical Engineering Society

Moderator:Xu Qian

Guest: 

● Wang Jue, Chairman of Suzhou Liangyihui Network Technology Co., Ltd.

● Wang Hui, Deputy General Manager of SCOR China and General Manager of Life & Health Insurance

● Chen Kai, Director of Digitalization and Business Innovation, AstraZeneca Investment (China) Co., Ltd.

● Sun Yuhui, Chairman of Vistel

Moderator: Su Zhenbo

Guest： 

● Gao Yi, Director of the Institute of Regenerative Medicine, Southern Medical University

● Leng Qibin, Deputy Director of the Center for Cancer Immunology, Guangzhou Medical University

● Professor Li Jiang, Center for Biotherapy, Sun Yat-sen University Cancer Center

● Wang Cheng, CEO of Beijing InnoVico Biopharmaceutical Technology Co., Ltd.

Host:Li Jie

Guest: 

● Ding Ke, Dean of the School of Pharmacy, Jinan University

● Xie Zhi, Executive Vice Dean of the National Institute of Health and Medical Big Data at Sun Yat-sen University

● Wang Luquan, CEO of Xinhua (Guangzhou) Biotechnology Co., Ltd.

● Wang Meijie, CEO of Shanghai Yuanxin Zhiyao; Fan Yichao, Vice Director of Investment at the AstraZeneca-CICC Healthcare Industry Fund

Following the five major roundtable discussions, five companies from the healthcare and wellness sector took the stage, engaging in in-depth exchanges and resource matching with investors and industry experts on multiple hot topics and solutions within the industry.

New Forces Enterprise Roadshow

Meanwhile, the closed-door meeting of Danlu Capital was also held concurrently.

Lu Qinchao and Su Zhenbo, two partners of Danlu Capital, together with their team members, presented to the investors in attendance on the fund’s investment performance and operational management over the past year. They provided a detailed exposition of Danlu Capital’s investment strategy, the post-investment development of its portfolio companies, and subsequent value-added services such as empowerment support.

At a closed-door conference, Su Zhenbo, Founding Partner of Danlu Capital, stated that as a relatively typical VC 2.0 fund, Danlu Capital has achieved favorable results since its official operations began in 2018.

During the fund project reporting session, the investment team of Danlu Capital provided a detailed overview of the full-year 2021 project progress and value-added post-investment services, highlighting the key strengths of its portfolio companies to comprehensively showcase investment outcomes to investors from multiple perspectives.

Danlu Capital focuses on investments in the big health and life sciences sectors. It currently manages two RMB-denominated funds and one USD-denominated fund, and has invested in more than 30 high-growth innovative companies. Among these portfolio companies, two (Breo and Cofoe Medical) completed their initial public offerings in 2021, while the majority have successfully secured new rounds of financing, demonstrating strong operational performance.

With this, the Guangzhou Sub-forum of the 2nd China Lifestyle Medicine Conference (CLMC) and the Grand Health & Life Sciences Industry-Finance Summit concluded successfully.

Thank you to all the distinguished guests who participated in this summit. See you next year!

Danlu Capital is a venture capital firm dedicated to the healthcare and medical industry. Co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner at Fenxiang Investment Management, the firm has consistently focused on early-stage investments in the broader healthcare sector. It has systematically built a portfolio spanning innovative medical technologies—including high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health—as well as innovative drugs and novel healthcare services.

Danlu Capital is committed to rewarding investors with strong performance and aims to leverage capital to accelerate the R&D and commercialization of modern medical and pharmaceutical technologies, thereby improving public health outcomes and establishing itself as a trusted, enduring, and premier healthcare fund management firm.